Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05607108
Other study ID # 22-286
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 1, 2022
Est. completion date November 2025

Study information

Verified date December 2023
Source Memorial Sloan Kettering Cancer Center
Contact Paul Paik, MD
Phone 646-608-3759
Email paikp@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date November 2025
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically-confirmed squamous cell lung cancer - Recurrent or metastatic disease - Patients with previously treated asymptomatic brain metastases requiring no more than 10mg prednisone (or equivalent) are allowed. Patients with asymptomatic brain metastases = 1cm not requiring more than 10mg prednisone (or equivalent) are allowed. - Received prior first-line therapy: platinum-based chemotherapy and immunotherapy, given either concurrently or sequentially - Eastern Cooperative Oncology Group (ECOG) PS 0-2 - Evidence of NSD3 gain or amplification by NGS, including but not limited to evidence of 8p11 gain or amplification as determined by MSK IMPACT or MSK ACCESS, or a commercially available molecular assay that is FDA authorized. Note: ctDNA testing, including but not limited to MSK ACCESS and Guardant and Foundation - Adequate laboratory parameters at Screening including: - Absolute neutrophil count (ANC) = 1.5 x 10^9/L - Platelet count = 100,000/mm^3 - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.0 ULN (= 5 x ULN if liver metastases are present) - Total bilirubin = 1.25 x ULN - Calculated or measured eGFR = 40 ml/min or serum creatinine = 1.5 x ULN - Prothrombin time (PT), international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x ULN - Ability to swallow capsules - Use of corticosteroids is allowed up to a daily dose of 10 mg prednisone or equivalent provided that the dose has been stable for at least 2 weeks prior to the start of ZEN003694 dosing and will remain stable during ZEN003694 treatment. - Females or males age = 18 years (at time of signing informed consent) - Female subjects may be enrolled if they are not of childbearing potential, permanently sterile or who are post-menopausal defined as no menses for at least 1 year without an alternative medical cause and FSH levels in the post-menopausal range. Female subjects of childbearing potential may be enrolled if they consistently and correctly use a highly effective form of contraception. Highly effective forms of contraception include: combined (estrogen and progestogen hormonal contraceptives (oral, intravaginal, transdermal) associated with inhibition of ovulation; progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence. Female subjects should not donate eggs from the time point of study drug administration until at least 7 months thereafter. - Males with partners of childbearing potential may be enrolled if they use a condom when having sex with a pregnant woman or with a non-pregnant female of childbearing potential from 21 days before the first dose of study drug through 4 months after the last dose of study drug, and males should not donate sperm from the time point of study drug administration until at least 4 months thereafter. Contraception should be considered for a non-pregnant female partner of childbearing potential - Females of childbearing potential must have a negative serum or urine pregnancy test before the first dose of study drugs and must agree to pregnancy tests during the study. - Females may not be breast-feeding at the first dose of study drugs, during study participation or through 7 months after the last dose of study drugs Exclusion Criteria: - Have previously received an investigational BET inhibitor - Have received prior systemic anti-cancer therapy or investigational therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first dose of study drug - Radiation therapy within 2 weeks of first dose of study drug - Currently receiving medications known to be strong inducers or inhibitors of CYP3A4 and substrates of CYP1A2 with a narrow therapeutic window. Strong inducers and inhibitors of CYP3A4 and CYP1A2 substrates with narrow therapeutic ranges must be discontinued at least 7 days prior to the first administration of study drug. - Left ventricular ejection fraction less than the lower of 50% or the lower limit of institution's normal range - QTcF interval > 470 msec - Known impaired cardiac function or clinically significant cardiac disease such as uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or uncontrolled congestive heart failure (New York Heart Association functional class III or IV) - Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug - Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, or any other condition that could compromise safety or the patient's participation in the study - Other known active cancer requiring therapy at time of study entry - Historically positive (screening tests not required) for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections. HBV positivity defined by positive hepatitis B surface antigen (HBsAg). HCV positivity defined as positive HCV viral load. - Major surgery other than diagnostic surgery, dental surgery or stenting within 4 weeks prior to the first administration of study drug - History of congenital or other deficiency in platelet function, or any known inherent or acquired coagulopathy, including current anticoagulation therapy (except for low-dose warfarin for port patency) - Current or anticipated use within 7 days prior to the first administration of study drug, or during the study, of strong P-gp inhibitors. - Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed. Note: except for subjects on anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZEN003694
ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle

Locations

Country Name City State
United States Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities Basking Ridge New Jersey
United States Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) Commack New York
United States Memorial Sloan Kettering Westchester (All Protocol Activities) Harrison New York
United States Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York
United States Memorial Sloan Kettering Nassau (All Protocol Activities) Uniondale New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Zenith Epigenetics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary overall response rate (ORR) Response to ZEN003694 will be determined using the sum unidimensional measurements of the target lesions present on the scan. Unidimensional measurement rules will adhere to RECIST 1.1 guidelines.(6) Classification of response will be categorized by RECIST 1.1 (CR, PR, SD, PD). 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Withdrawn NCT03346304 - Photodynamic Therapy for the Prevention of Lung Cancer Phase 2/Phase 3
Recruiting NCT02288026 - Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer N/A
Terminated NCT01491633 - Dasatinib in Advanced Squamous Cell Lung Cancer Phase 2
Completed NCT00087412 - S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Phase 2
Completed NCT00049543 - Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Phase 3
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Recruiting NCT02787473 - A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer Phase 2
Completed NCT00387374 - Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Phase 2
Completed NCT00002852 - Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase 3
Recruiting NCT05550961 - APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Active, not recruiting NCT05292859 - Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Terminated NCT03574818 - Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 Phase 2
Suspended NCT00909558 - Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer Phase 1
Completed NCT00040794 - Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Phase 2
Terminated NCT00042835 - Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Phase 1
Terminated NCT03827850 - FGFR Inhibitor in FGFR Dysregulated Cancer Phase 2
Active, not recruiting NCT01345851 - Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery N/A
Withdrawn NCT02059967 - Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Phase 1
Completed NCT01082549 - Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Phase 3